Based on the third quarter report disclosure for 2024, several IVD companies listed on the STAR Market have demonstrated a positive trend in their performance. The strategic implementation of overseas market layout has been carried out steadily, leading to a continuous enhancement in overall competitiveness.
Currently, nine IVD companies listed on the STAR Market have reported year-on-year growth in operating revenue. Innovita and Sansure Biotech have seen increases exceeding 50%. Twelve companies are profitable, and nine companies have achieved positive growth in net profit after excluding non-recurring items.
With the ongoing refinement of the national hierarchical healthcare system and significant improvements in domestic awareness regarding early diagnosis and treatment, demand for routine services such as primary care and home-based diagnosis is rising. IVD companies on the STAR Market, including Innovita, Vazyme Biotech, LBP, Sansure Biotech, and BioPerfectus, are seizing these market opportunities, resulting in vigorous growth.
STAR Market-listed IVD companies are targeting overseas markets by broadly expanding in product registration and distribution channels, and focusing on creating a second growth engine for business performance. On the product front, more than 15 products have been approved for registration in foreign markets from January to September this year. Regarding distribution channels, relevant companies are accelerating their marketing strategies abroad, resulting in a noticeable increase in market coverage.
Apart from accelerating R&D and expanding overseas presence, these listed companies are also enhancing investor returns through interim cash dividends and share buybacks. Statistics show that the interim cash dividends and share buybacks executed by these companies in the first three quarters total RMB 1.636 billion.
From Shanghai Securities News—www.cnstock.com on October 29, 2024
See full article at:https://www.cnstock.com/commonDetail/297914
The above information is provided for reference purposes only and does not constitute investment advice.
